Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Tamminen, J A ^a,b   Parviainen, V ^b   Ronty M ^a,c   Wohl, A P ^d   Murray, L ^a,b   Joenvaara S ^b   Varjosalo, M ^e   Lepparanta O ^a   Ritvos, O ^a,c   Sengle, G ^d   Renkonen, R ^b,c   Myllarniemi M ^a   Koli, K ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

EMT; Fibrillin; Gremlin; Mesothelioma; Slug

Indexed keywords

FIBRILLIN 2; GREMLIN 1 PROTEIN; PACLITAXEL; PEMETREXED; PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG RESISTANCE; EMBRYO DEVELOPMENT; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBER; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84883234440     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.29     Document Type: Article

References (53)

1. Mossman BT, Bignon J, Corn M, Seaton A, Gee JB. Asbestos: scientific developments and implications for public policy. Science 1990; 247: 294-301.
2. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992; 34: 718-721.
3. Huuskonen MS, Rantanen J. Finnish Institute of Occupational Health (FIOH): prevention and detection of asbestos-related diseases, 1987-2005. Am J Ind Med 2006; 49: 215-220.
4. Vorobiof DA, Mafafo K. Malignant pleural mesothelioma: medical treatment update. Clin Lung Cancer 2009; 10: 112-117.
5. Dormoy V, Jacqmin D, Lang H, Massfelder T. From development to cancer: lessons from the kidney to uncover new therapeutic targets. Anticancer Res 2012; 32: 3609-3617.
6. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010; 15: 117-134.
7. Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol Cell 1998; 1: 673-683.
8. Topol LZ, Bardot B, Zhang Q, Resau J, Huillard E, Marx M et al. Biosynthesis, posttranslation modification, and functional characterization of Drm/Gremlin. J Biol Chem 2000; 275: 8785-8793.
9. Sengle G, Charbonneau NL, Ono RN, Sasaki T, Alvarez J, Keene DR et al. Targeting of bone morphogenetic protein growth factor complexes to fibrillin. J Biol Chem 2008; 283: 13874-13888.
10. Michos O, Panman L, Vintersten K, Beier K, Zeller R, Zuniga A et al. antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development 2004; 131: 3401-3410.
11. Topol LZ, Marx M, Laugier D, Bogdanova NN, Boubnov NV, Clausen PA et al. Identification of drm, a novel gene whose expression is suppressed in transformed cells and which can inhibit growth of normal but not transformed cells in culture. Mol Cell Biol 1997; 17: 4801-4810.
12. Namkoong H, Shin SM, Kim HK, Ha SA, Cho GW, Hur SY et al. The bone morphogenetic protein antagonist gremlin 1 is overexpressed in human cancers and interacts with YWHAH protein. BMC Cancer 2006; 6: 74.
13. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancerassociated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci USA 2006; 103: 14842-14847.
14. Varjosalo M, Sacco R, Stukalov A, van Drogen A, Planyavsky M, Hauri S et al. Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. Nat Methods 2013; 10: 307-314.
15. Ramirez F, Sakai LY. Biogenesis and function of fibrillin assemblies. Cell Tissue Res 2010; 339: 71-82.
16. Koli K, Myllärniemi M, Vuorinen K, Salmenkivi K, Ryynänen MJ, Kinnula VL et al. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am J Pathol 2006; 169: 61-71.
17. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
18. Catalano A, Rodilossi S, Rippo MR, Caprari P, Procopio A. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem 2004; 279: 46706-46714.
19. Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012; 12: 91.
20. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
21. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
22. Wang DJ, Zhi XY, Zhang SC, Jiang M, Liu P, Han XP et al. The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma. Oncol Rep 2012; 27: 58-64.
23. Brinckmann J, Hunzelmann N, Kahle B, Rohwedel J, Kramer J, Gibson MA et al. Enhanced fibrillin-2 expression is a general feature of wound healing and sclerosis: potential alteration of cell attachment and storage of TGF-b. Lab Invest 2010; 90: 739-752.
24. Leppäranta O, Sens C, Salmenkivi K, Kinnula VL, Keski-Oja J, Myllärniemi M et al. Regulation of TGF-b storage and activation in the human idiopathic pulmonary fibrosis lung. Cell Tissue Res 2012; 348: 491-503.
25. Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504.
26. Lin G, Tiedemann K, Vollbrandt T, Peters H, Batge B, Brinckmann J et al. Homoand heterotypic fibrillin-1 and-2 interactions constitute the basis for the assembly of microfibrils. J Biol Chem 2002; 277: 50795-50804.
27. Ramirez F, Rifkin DB. Extracellular microfibrils: contextual platforms for TGFb and BMP signaling. Curr Opin Cell Biol 2009; 21: 616-622.
28. Dallas SL, Chen Q, Sivakumar P. Dynamics of assembly and reorganization of extracellular matrix proteins. Curr Top Dev Biol 2006; 75: 1-24.
29. Koli K, Hyytiäinen M, Ryynänen MJ, Keski-Oja J. Sequential deposition of latent TGF-b binding proteins (LTBPs) during formation of the extracellular matrix in human lung fibroblasts. Exp Cell Res 2005; 310: 370-382.
30. Gordon KJ, Kirkbride KC, How T, Blobe GC. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2. Carcinogenesis 2009; 30: 238-248.
31. Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL, Kim JS et al. Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-kB pathway, and MMP-9 expression. Exp Cell Res 2011; 317: 1746-1762.
32. Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, Iwase T et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 2008; 27: 6322-6333.
33. Kim M, Yoon S, Lee S, Ha SA, Kim HK, Kim JW et al. Gremlin-1 induces BM Pindependent tumor cell proliferation, migration, and invasion. PLoS One 2012; 7: e35100.
34. Mulvihill MS, Kwon YW, Lee S, Fang LT, Choi H, Ray R et al. Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. PLoS One 2012; 7: e42264.
35. Sneddon JB, Werb Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell 2007; 1: 607-611.
36. Kosinski C, Li VS, Chan AS, Zhang J, Ho C, Tsui WY et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA 2007; 104: 15418-15423.
37. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H et al. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175. types of healthy and pathological tissues. Genome Biol 2008; 9: R139.
38. Chen B, Athanasiou M, Gu Q, Blair DG. Drm/Gremlin transcriptionally activates p21(Cip1) via a novel mechanism and inhibits neoplastic transformation. Biochem Biophys Res Commun 2002; 295: 1135-1141.
39. Wang H, Zhang Q, Wen Q, Zheng Y, Lazarovici P, Jiang H et al. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal 2012; 24: 17-24.
40. Carvajal G, Droguett A, Burgos ME, Aros C, Ardiles L, Flores C et al. Gremlin: a novel mediator of epithelial mesenchymal transition and fibrosis in chronic allograft nephropathy. Transplant Proc 2008; 40: 734-739.
41. Lee H, O'Meara SJ, O'Brien C, Kane R. The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 2007; 48: 4291-4299.
42. Shih JY, Yang PC. The EMT regulator slug and lung carcinogenesis. Carcinogenesis 2011; 32: 1299-1304.
43. Fassina A, Cappellesso R, Guzzardo V, Dalla Via L, Piccolo S, Ventura L et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol 2012; 25: 86-99.
44. Merikallio H, Pääkko P, Salmenkivi K, Kinnula V, Harju T, Soini Y. Expression of snail, twist, and Zeb1 in malignant mesothelioma. APMIS 2012; 121: 1-10.
45. Pasello G, Ceresoli GL, Favaretto A. An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma. Cancer Treat Rev 2013; 39: 10-17.
46. Mitola S, Ravelli C, Moroni E, Salvi V, Leali D, Ballmer-Hofer K et al. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood 2010; 116: 3677-3680.
47. Ke Y, Reddel RR, Gerwin BI, Reddel HK, Somers AN, McMenamin MG et al. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol 1989; 134: 979-991.
48. Koli K, Ryynänen MJ, Keski-Oja J. Latent TGF-b binding proteins (LTBPs)-1 and-3 coordinate proliferation and osteogenic differentiation of human mesenchymal stem cells. Bone 2008; 43: 679-688.
49. Myllärniemi M, Lindholm P, Ryynänen MJ, Kliment CR, Salmenkivi K, Keski-Oja J et al. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177: 321-329.
50. Glatter T, Wepf A, Aebersold R, Gstaiger M. An integrated workflow for charting the human interaction proteome: insights into the PP2A system. Mol Syst Biol 2009; 5: 237.
51. Fenyo D, Eriksson J, Beavis R. Mass spectrometric protein identification using the global proteome machine. Methods Mol Biol 2010; 673: 189-202.
52. Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Ma H, Pierre P et al. Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins. Am J Physiol Endocrinol Metab 2013; 304: E41-E50.
53. Tamminen JA, Myllärniemi M, Hyytiäinen M, Keski-Oja J, Koli K. Asbestos exposure induces alveolar epithelial cell plasticity through MAPK/Erk signaling. J Cell Biochem 2012; 113: 2234-2247.